Compare Li Auto Inc (LI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Tango Therapeutics Inc. — how do they compare? Li Auto Inc trades at $11.27 (market cap $11.27B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Li Auto Inc is far larger — about 3× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 102 Days and Tango Therapeutics Inc. for 0 Days on average.
| LI | TNGX | |
|---|---|---|
Market Cap | $11.27B | $3.75B |
Volume | 3,921,121 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.72 | $32.90 |
52-Week Low | $10.69 | $7.50 |
Typical Hold Time | 102 Days | 0 Days |
Enterprise Value | $673.48M | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $11.26, down 1.23% on the day and near its 52-week low, reflecting bearish technical signals and recent delivery declines. The company reported revenue of $112.31B in 2025 with a net income of $1.12B, but profitability metrics like net income margin and ROE remain negative. Recent news highlights challenges in China's EV market, with September 2026 deliveries of 31,817 vehicles showing moderation. Analyst consensus is mixed, with a $15.18 price target suggesting potential upside from current levels.
The outlook for LI is cautious due to intense competition and cash flow pressures, with net cash flow negative $9.0B in 2025. Investment opportunities include new model launches like the Li i9 SUV and global expansion, but risks from market volatility and execution missteps persist. Investors should weigh the company's solid balance sheet against near-term headwinds.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
